Introduction {#s0001}
============

A healthy kidney is essential for glucose homeostasis. Kidney filters glucose and subsequently reabsorbs the filtered glucose or excretes it into urine; it uptakes glucose for its energy needs; and also releases into circulation the glucose that it has newly synthesized via gluconeogenesis.[@CIT0001] Obesity, metabolic syndrome, and diabetes generate unfavorable changes in the kidney tissue and alter its functions.

Chronic kidney disease (CKD) can be initiated by hyperglycemia and lead to diabetic nephropathy (DN), which is the major cause of end-stage renal disease (ESRD).[@CIT0002] Evidence suggests that DN develops much earlier in the course of the disease; there seems to be 4--7 years of asymptomatic phase between the onset of hyperglycemia and the actual clinical diagnosis of type 2 diabetes (T2D). During this lag period, chronic complications of diabetes, such as nephropathy, retinopathy, and cardiovascular disease that are caused mainly by micro- and macro-vascular changes in the endothelium of blood vessels, and metabolic acidosis, continue to develop in disguise.[@CIT0003]^,^[@CIT0004]

Although microalbuminuria is an important stage of kidney disease in diabetes,[@CIT0005] it has been reported that kidney damage can occur without evident proteinuria or microalbuminuria. High-fat diet, for example, can cause significant kidney damage without any evidence of proteinuria or hyperglycemia. In addition, hyperglycemia and hypertension are needed for the presence of protein in urine.[@CIT0006]^,^[@CIT0007] But, as diabetic patients often suffer from both hyperglycemia, hyperlipidemia, as well as hypertension, they are susceptible to kidney complications; therefore, traditional biomarkers including macro and microalbuminuria, and creatinine, as a marker of estimated glomerular filtration rate (eGFR), can still be used in the detection and monitoring of kidney damages.[@CIT0008]

We have previously shown the hypoglycemic and antihyperlipidemic effects of lyophilized *Cichorium intybus* L. aqueous seed extract (CSE).[@CIT0014]^,^[@CIT0015] The aim of the present study was to test the usefulness of CSE in preventing diabetes-induced kidney damage. A number of DN biomarkers, such as urea, BUN, uric acid, creatinine, albumin, α1-microglobulin, total protein, sodium, potassium, and GFR were measured in serum and urine, and in the renal tissue samples of rats with early type 2 diabetes (ET2D) and late type 2 diabetes (LT2D).[@CIT0016] We also noted kidney histology and the expression of Na^+^/glucose cotransporters in kidney tissue homogenates. Metformin and aspirin were used as controls.

Materials and methods {#s0002}
=====================

All the experiments were performed on the sera, urine samples and kidney tissues obtained from rats used in another study.[@CIT0016]

Preparation of plant extract, metformin and aspirin {#s0003}
---------------------------------------------------

The lyophilized powder of CSE that was stored at −20 °C belonged to a previous study from our laboratory.[@CIT0014] Metformin and aspirin pills (Chemidaru industrial company, Tehran, Iran) were purchased from a drug store and crushed manually.

Animals {#s0004}
-------

### Animal care {#s0005}

Animal handling and treatment were performed in the Biochemistry Department of the School of Medicine, Tehran University of Medical Sciences (TUMS). Healthy adult male 8-week old Wistar albino rats weighing 190--260 g were obtained from University of Tehran, Institute of Biochemistry and Biophysics and housed in standard and clean cages (2 per cage) in animal room (temperature 22 ± 2 °C) and 12-h light/dark cycle with access to a standard rat chow and water *ad libitum*. The study was ethically approved by the review board of TUMS.

### Induction of experimental diabetes {#s0006}

In brief, early and late stage type 2 diabetes (ET2D and LT2D) were induced in overnight fasted rats by single intraperitoneal injections of streptozotocin (STZ, 55 mg/kg) or combination of STZ (55 mg/kg) and niacinamide (NIA, 200 mg/kg, 15 min later), dissolved in chilled citrate buffer (0.3 ml).[@CIT0014] Hyperglycemia was confirmed on days 4 and 10 after injection by measuring glucose levels in peripheral blood obtained from the tail vein (GlucoSure STAR, ApexBio, Taiwan). STZ-injected rats with fasting blood sugar (FBS) above 300 mg/dl in both occasions (day 4 and day 10) were considered as LT2D rats, and NIA/STZ-injected rats with stable FBS ranging between 140 and 220 mg/dl were considered as ET2D.[@CIT0016] Normal rats received an injection of the vehicle without either STZ or NIA. STZ and NIA were obtained from Sigma-Aldrich Co. (St. Louis, MO).

### Experimental design, group designation and treatment {#s0007}

After diabetes induction, rats were assigned into nine groups (*n* = 6) as presented in [Figure 1](#F0001){ref-type="fig"} and treatment was started on day 10. Groups 1 (Control, non-diabetic), 3 (NIA/STZ or ET2D), and 6 (STZ or LT2D) received injections of the vehicle (0.3 ml). Groups 2 (CSE-control), 4 (CSE-NIA/STZ), and 7 (CSE-STZ) were injected with CSE. Groups 5 (Met-NIA/STZ) and 8 (Met-STZ) were injected with metformin. The injections of CSE and metformin were daily and intraperitoneal, and lasted for 21 days (3 weeks); Group 9 (Asp-STZ) received daily aspirin orally by gavage. According to weekly body weights, certain amounts (mg) of CSE, metformin, and aspirin were pre-weighed in separate microtubes and kept in refrigerator; they were mixed with 0.3 ml of manually prepared and autoclaved citrate buffer (20 mM, pH 4.5) immediately before administration.[@CIT0016]

![Rat groups. Duration of treatment, 21 days. Treatments included: CSE, 125 mg; metformin, 100 mg; and aspirin, 120 mg; per body weight per day.](IRNF_A_1256317_F0001_C){#F0001}

### Sample collection {#s0008}

At the end of the treatment time (day 31), animals were placed individually in metabolic cages for 24 h urine collection with access to water overnight. After measuring the volume, urine samples were acidified with 1 ml of 0.1 M HCL and centrifuged at 1200 rpm for 15 min; aliquots were stored at −80 °C. The rats were anesthetized with diethyl ether and sacrificed. Blood samples were collected for biochemical analysis by direct cardiac puncture and sera were separated by centrifugation at 3000 rpm for 15 min. The kidneys were submerged in liquid nitrogen after separation from the body and stored at −80 °C.

### Biochemical analysis {#s0009}

Measurement of urea, uric acid, creatinine and albumin in serum and urine was performed by spectrophotometric methods using diagnostic kits (Ziest Chem Diagnostics, Tehran, Iran). A kit from the same company based on the Biuret method was used to determine total protein in the serum, and the Bradford method was used to measure total protein in tissue homogenates and urine samples.[@CIT0017] ELISA (NovaTeinBio, Woburn, MA) was used to measure α1-microglobulin in serum and urine. Sodium and potassium levels in serum were measured by flame-photometry. Glucose level in urine was measured by glucose oxidase activity assay kit (Ziest-Chem, Iran). GFR was calculated according to the following formula: $${Clearance}\quad({mg}/\min) = \frac{{Urine}\quad{Creatinine}\quad(\frac{mg}{dl})*{Urine}\quad{Volume}\quad({ml})}{{Serum}\quad{Creatinine}\quad\left( \frac{mg}{dl} \right)*1440}$$

### Histological observation {#s0010}

A small piece of frozen kidney tissues of all groups were fixed in an aqueous solution of 10% formaldehyde, dehydrated in graduated ethanol (50--100%), cleared in xylene, and embedded in paraffin. Renal sections (5 μm) were examined with a photomicroscope (400×) after staining with hematoxylin and eosin (H&E) dye.

### Membrane preparation for SGLT1 and SGLT2 blotting {#s0011}

Half of each kidney tissue was homogenized in chilled buffer A (137 mM NaCl, 8.1 mM Na~2~HPO~4~, 2.7 mM KCl, 1.5 mM KH~2~PO~4~, 2.5 mM EDTA, 1 mM dithiothreitol, 0.2 mM PMSF, mM cocktail) by hand homogenizer and further by trituration with insulin syringe. Lysates were first centrifuged at 6000*g* for 15 min at 4 °C. The supernatants were centrifuged at 120,000*g* for 1 h at 4 °C to prepare cytosolic and total particulate fractions. The total particulate fractions, which contained membrane fraction, were washed twice and resuspended in buffer A containing 1% (v/v) Triton X-100.[@CIT0018] After centrifugation, the protein in each fraction was quantified by the Bradford procedure.

### Western blot analysis {#s0012}

For each electrophoresis lane, equal amounts of protein (30 μg) were mixed with loading buffer and boiled for five minutes. Samples were separated on an 8% sodium dodecyl sulfate-polyacrylamide gel and then transferred to polyvinylidene fluoride (PVDF) membrane. PVDF blots were blocked by incubation in PBST (20 mM PBS, pH 7.4, and 0.1% Tween 20) containing 5% nonfat skim milk overnight at 4 °C and then incubated with a rabbit polyclonal antibodies against SGLT1 (1: 1000 dilution), SGLT2 (1: 200 dilution), and β-actin (1: 3000 dilution) for 2 h at 37 °C (Abcam Inc., Cambridge, MA). After three washing steps (PBST, each step 5 min), a horseradish peroxidase (HRP)-conjugated polyclonal secondary anti-rabbit antibody (1: 20,000 dilution) was added and incubated for 1 h. After three washing steps, the bands were visualized with enhanced chemiluminescence detection kit (ECL) (Thermo Scientific, Waltham, MA). Image J software (NIH) was used for densitometric analysis of the bands.

### Statistical analysis {#s0013}

Statistical analysis was performed by SPSS software (version 20, Chicago, IL). Normal distribution of continuous variables was checked by the Kolmogrov--Smirnov test in each group. All variables in each group had normal distribution, so the comparison of continuous variables between different groups was carried out by one-way analysis of variance (ANOVA) followed by the Scheffe and Dunnett T3 *post hoc* tests. Data were presented as the mean ± standard deviation (SD). The level of significance was considered .05. Pearson coefficients were measured for association between continuous variables.

Results {#s0014}
=======

Body weights and FBS {#s0015}
--------------------

After diabetes induction, FBS levels increased significantly to \>300 mg/dl in STZ groups (LT2D), and ranged between 140 and 220 mg/dl in NIA/STZ groups (ET2D); the LT2D rats lost significant weight, but weight loss was not significant in NIA/STZ-induced diabetes (ET2D).[@CIT0016] The percent changes of FBS and body weight at the end of treatment (day 31) versus start of treatment (day 10) are shown in [Figure 2](#F0002){ref-type="fig"}; CSE significantly lowered FBS (*p* \< .001) and increased body weight (*p* = .032) in ET2D rats.

![Comparison of body weights and FBS levels after confirmation of diabetes induction (day 10, black bar) vs. at the end of study time (day 31, white bar). \**p* \< .001; †*p* = .032.](IRNF_A_1256317_F0002_C){#F0002}

Blood and urine parameters in the final day of treatment (day 31) {#s0016}
-----------------------------------------------------------------

### Untreated diabetic groups {#s0017}

Induction of LT2D led to significant increase in several serum variables, including uric acid (*p* = .04), creatinine (*p* \< .001), urea (*p* = .001), and BUN (*p* = .001); and a decrease in albumin levels (*p* = .047) ([Table 1](#t0001){ref-type="table"}). Again in serum, changes common to both types of diabetes were a decrease in Na^+ ^(*p* = .007) due to diabetic hyperosmolar state, an increase in K^+ ^(*p* \< .001) due to lack of enough insulin and the resulting disturbances of internal potassium balance, and a decrease in serum α1-microglobulin levels (*p* = .002 for LT2D; *p* = .011 for ET2D).[@CIT0019] Urine volume (*p* \< .001 for LT2D; *p* = .01 for ET2D), α1-microgobulin (*p* = .001 for LT2D; *p* = .006 for ET2D), and total protein (*p* = .006 for ET2D; *p* = .018 for LT2D) increased after induction of both types of diabetes ([Table 2](#t0002){ref-type="table"}). Urinary levels of glucose (*p* = .001), uric acid (*p* = .002), creatinine (*p* = .005), and urea (*p* \< .001) increased in LT2D, and albumin levels increased in ET2D (*p* = .042). There was a strong correlation between 24 h urine urea and creatinine perhaps due to excessive loss of muscle mass ([Figure 3(A)](#F0003){ref-type="fig"}; Pearson correlation = .889, *p* \< .001). Correlation between urine α1-microglobulin and serum uric acid was stronger (Pearson coefficient = .811, *p* = .001) than the correlation between urine albumin and serum uric acid (Pearson coefficient = .399, *p* = .112) ([Figure 3(B,C)](#F0003){ref-type="fig"}).

![Correlation coefficients between 24 h urine urea and creatinine (A), urine albumin and serum uric acid (B), and urine α1-microglobulin and serum uric acid (C).](IRNF_A_1256317_F0003_C){#F0003}

###### 

Summary statistics of serum variables values after diabetes induction and 21 days of treatments.

  Blood parameter                                                    Non-diabetic (control)   Early type 2 diabetes   Late type 2 diabetes                                                                                              
  ------------------------------------------------------------------ ------------------------ ----------------------- ---------------------- ------------------- --------------- ----------------- ----------------- ------------------ ------------------
  FBS^a‡,b‡,c‡^                                                      107.8 ± 11.1             103.5 ± 6.1             *305.4 ± 88.4*         **82.3 ± 10.2**     307.4 ± 156.7   *398.6 ± 25.5*    365.4 ± 44.5      371.0 ± 67.9       454.8 ± 72.1
  Uric acid[^b^](#TF2){ref-type="table-fn"}^\*,e\*,f\*^ (mg/dl)      1.75 ± 0.13              1.47 ± 0.23             1.99 ± 0.22            1.68 ± 0.26         1.25 ± 0.46     *2.83 ± 0.49*     **1.58 ± 0.46**   1.64 ± 0.47        2.24 ± 0.80
  Creatinine[^b^](#TF2){ref-type="table-fn"}^‡,g‡^ (mg/dl)           1.13 ± 0.08              1.07 ± 0.09             1.29 ± 0.10            0.93 ± 0.20         1.42 ± 0.13     *1.62 ± 0.25*     1.42 ± 0.16       1.73 ± 0.20        **1.77 ± 0.15**
  Urea[^b^](#TF2){ref-type="table-fn"}^\*,c†,f†,g\*^ (mg/dl)         42.93 ± 3.70             38.25 ± 4.53            49.11 ± 2.56           **39.73 ± 2.46**    56.89 ± 5.36    *74.87 ± 8.22*    77.71 ± 6.73      **53.01 ± 9.03**   **44.75 ± 4.51**
  BUN[^b^](#TF2){ref-type="table-fn"}^†,c†,f\*,g†^ (mg/dl)           20.06 ± 1.73             17.87 ± 2.11            22.95 ± 1.19           **18.56 ± 1.15**    26.58 ± 2.50    *34.98 ± 3.84*    36.31 ± 3.15      **24.77 ± 4.22**   **20.91 ± 2.11**
  BUN/Creatinine[^h^](#TF8){ref-type="table-fn"}^†^                  17.68 ± 1.40             16.82 ± 2.82            17.86 ± 1.52           20.77 ± 5.00        18.72 ± 1.30    22.42 ± 6.99      25.85 ± 4.19      14.47 ± 3.26       11.88 ± 1.80
  Albumin[^b^](#TF2){ref-type="table-fn"}\* (g/dl)                   3.23 ± 0.41              3.11 ± 0.13             2.53 ± 0.20            2.81 ± 0.09         2.65 ± 0.23     *2.36 ± 0.24*     2.43 ± 0.25       2.53 ± 0.16        2.56 ± 0.23
  Total protein (g/dl)                                               7.51 ± 0.39              7.37 ± 0.39             7.28 ± 0.64            7.52 ± 0.44         7.29 ± 0.50     7.15 ± 0.29       6.99 ± 0.16       7.11 ± 0.26        7.08 ± 0.59
  α-1-microglobulin[^a^](#TF1){ref-type="table-fn"}^\*,b†^ (pg/ml)   174.22 ± 14.35           166.91 ± 9.22           *83.95 ± 20.73*        114.16 ± 11.44      80.0 ± 10.25    *87.5 ± 10.02*    89.16 ± 7.66      85.20 ± 13.16      77.72 ± 10.55
  Sodium[^a^](#TF1){ref-type="table-fn"}^†,b‡,c\*^ (meq/l)           158.91 ± 2.80            160.21 ± 3.57           *149.1 ± 3.48*         **156.87 ± 2.83**   --              *147.32 ± 4.44*   148.72 ± 3.26     --                 --
  Potassium[^a^](#TF1){ref-type="table-fn"}^†,b‡,c†^ (meq/l)         6.07 ± 0.19              6.02 ± 0.25             *7.7 1 ± 0.26*         **6.86 ± 0.49**     --              *7.92 ± 0.16*     7.82 ± 0.34       --                 --

Control vs. NIA/STZ.

Control vs. STZ.

NIA/STZ vs. CSE-NIA/STZ.

NIA/STZ vs. Met-NIA/STZ.

STZ vs. CSE-STZ.

STZ vs. Met-STZ.

STZ vs. Asp-STZ.

Control vs. Asp-STZ. Data are presented as mean ± SD.

\*,†, and ‡ indicate *p* \< .05, *p* \< .01, and *p* \< .001, respectively. Italic numbers show significant differences vs. non diabetic control; bold numbers show significant differences vs. the untreated diabetic groups.

###### 

Summary statistics of 24 h urine variables values after diabetes induction and 21 days of treatments.

  Urine parameter                                                           Non-diabetic (control)   Early type 2 diabetes   Late type 2 diabetes                                                                                                            
  ------------------------------------------------------------------------- ------------------------ ----------------------- ---------------------- ------------------ ---------------- --------------------- ---------------------- ----------------------- --------------------
  Urine volume[^a^](#TF10){ref-type="table-fn"}^\*,b‡,e\*,g‡^ (ml/day)      10.0 ± 3.9               8.5 ± 1.68              *33.8 ± 7.0*           27.1 ± 3.8         17.8 ± 7.0       *74.0 ± 9.4*          **52.5 ± 6.9**         60.6 ± 17.5             **19.8 ± 10.0**
  Glucose[^b^](#TF11){ref-type="table-fn"}^\*,e\*,f†,g†^ (mg/day)           0.68 ± 0.35              0.67 ± 0.18             1787.96 ± 883.61       42.15 ± 9.73       41.0 ± 28.02     *8676.89 ± 1037.73*   **5419.50 ± 973.35**   **4145.40 ± 1610.81**   **238.68 ± 57.97**
  Uric acid ^b†,g†^ (mg/day)                                                0.95 ± 0.10              1.34 ± 0.19             2.56 ± 0.69            2.46 ± 0.35        1.70 ± 0.40      *4.92 ± 0.89*         4.93 ± 1.44            4.98 ± 1.12             **1.31 ± 0.56**
  Creatinine[^b^](#TF11){ref-type="table-fn"}^†^ (mg/day)                   8.99 ± 1.31              9.99 ± 1.39             12.49 ± 3.13           16.30 ± 2.32       14.61 ± 3.79     *21.04 ± 3.71*        16.78 ± 3.30           21.02 ± 4.56            16.16 ± 10.17
  Urea[^b^](#TF11){ref-type="table-fn"}^‡,f\*,g\*^ (g/day)                  0.366 ± 0.07             0.399 ± 0.06            0.479 ± 0.06           0.449 ± 0.20       0.423 ± 0.16     *1.09 ± 0.12*         0.814 ± 0.17           **0.586 ± 0.19**        **0.464 ± 0.20**
  α-1-microglobulin[^a^](#TF10){ref-type="table-fn"}^†,b†,c\*^ (μg/day)     45.42 ± 7.22             44.86 ± 9.58            *166.49 ± 20.18*       **97.64 ± 7.00**   165.73 ± 15.46   *270.28 ± 20.74*      262.02 ± 25.14         252.71 ± 50.93          211.79 ± 22.33
  Albumin[^a^](#TF10){ref-type="table-fn"}\* (mg/day)                       21.76 ± 8.83             20.98 ± 3.64            *42.94 ± 7.25*         31.12 ± 3.72       30.05 ± 8.79     45.17 ± 22.42         46.87 ± 14.98          45.95 ± 11.83           54.88 ± 8.30
  Total protein[^a^](#TF10){ref-type="table-fn"}^†,b\*,g\*^ (mg/day)        65.3 ± 7.0               69.0 ± 5.5              *173.2 ± 25.2*         145.3 ± 19.5       110.2 ± 43.5     *261.9 ± 73.0*        223.7 ± 87.9           213.7 ± 67.3            **112.6 ± 40.3**
  GFR (ml/min)                                                              0.54 ± 0.06              0.64 ± 0.07             0.67 ± 0.18            1.25 ± 0.27        0.72 ± 0.19      0.91 ± 0.20           0.82 ± 0.16            0.84 ± 0.19             0.64 ± 0.45
  Albumin/Creatinine                                                        2.40 ± 0.81              2.12 ± 0.40             3.61 ± 1.12            1.94 ± 0.39        2.06 ± 0.24      2.15 ± 0.85           2.93 ± 1.13            2.32 ± 0.90             3.88 ± 0.92
  α-1-macroglobulin/Creatinine (μg/mg)[^i^](#TF17){ref-type="table-fn"}\*   5.31 ± 0.69              4.75 ± 1.01             14.91 ± 1.24           5.99 ± 0.73        10.59 ± 1.40     12.94 ± 2.07          17.11 ± 4.96           12.31 ± 3.52            14.20 ± 6.01
  Kidney glomerular diameter (μm)[^e^](#TF14){ref-type="table-fn"}^†^       838.06 ± 36.25           797.56 ± 37.82          767.36 ± 53.75         790.46 ± 22.17     842.13 ± 25.01   872.46 ± 49.78        **756.66 ± 11.45**     861.93 ± 33.49          956.70 ± 49.11

Control vs. NIA/STZ.

Control vs. STZ.

NIA/STZ vs. CSE-NIA/STZ.

NIA/STZ vs. Met-NIA/STZ.

STZ vs CSE-STZ.

STZ vs. Met-STZ.

STZ vs. Asp-STZ.

CSE-control vs. STZ. Data are presented as mean ± SD.

\*, †, and ‡ indicate *p* \< .05, *p* \< .01, and *p* \< .001, respectively. Italic numbers show significant differences vs. non-diabetic control; bold numbers show significant differences vs. the untreated diabetic groups.

### CSE-treated groups {#s0018}

CSE treatment decreased the level of urea (*p* = .005), BUN (*p* = .005), and K^+ ^(*p* = .006), and increased Na^+ ^(*p* = .037) in serum; it also significantly decreased urinary α1-microglobulin (*p* = .043) in CSE-STZ/NIA relative to the NIA/STZ group. In LT2D, uric acid levels in serum (*p* = .045), urine volume (*p* = .012), and urinary glucose (*p* = .021) decreased in the CSE-STZ group ([Tables 1](#t0001){ref-type="table"} and [2](#t0002){ref-type="table"}).

### Metformin-treated groups {#s0019}

In ET2D, treatment with metformin did not affect blood or urine biochemistry. In LT2D, metformin lowered blood concentrations of uric acid (*p* = .021), urea (*p* = .012), and BUN (*p* = .012); it also decreased urine glucose (*p* = .002) and urea (*p* = .001) ([Tables 1](#t0001){ref-type="table"} and [2](#t0002){ref-type="table"}).

### Aspirin-treated group {#s0020}

Urea (*p* = .001) and BUN (*p* = .001) decreased and creatinine (*p* \< .001) increased in blood under aspirin. Aspirin significantly reduced the urine volume (*p* \< .001), and urinary levels of glucose (*p* = .001), uric acid (*p* = .042), urea (*p* = .002), and total protein (*p* \< .05) in Asp-STZ relative to the STZ group ([Tables 1](#t0001){ref-type="table"} and [2](#t0002){ref-type="table"}).

### Histological observation {#s0021}

Kidney histology for normal rats (Control and CSE-control) and for those with ET2D and LT2D are shown in [Figures 4--6](#F0004 F0005 F0006){ref-type="fig"}. The average values of glomerular diameters measured from three perspectives for 10 glomeruli in each group are given in [Table 2](#t0002){ref-type="table"}. When compared to STZ-group, CSE caused a reduction in average glomerular diameter (*p* = .007). Aspirin, on the other hand, seemed to increase glomerular diameter (*p* = .83).

![H & E stained optical micrographs of kidney tissue morphology of normal non-diabetic rats before (Control) and after (CSE-control) treatment with chicory (×400). G: glomerulus; US, urinary space; DCT: distal convoluted tubules; UP: urinary pole.](IRNF_A_1256317_F0004_C){#F0004}

![H & E stained kidney histopathology micrographs of NIA/STZ (ET2D) group of rats before and after treatment with CSE and metformin (×400). E-T2D caused extensive irregularity in the glomerular basement membrane (GBM) and mild scleronecrosis. Treatment with CSE and metformin seemed to improve the condition.](IRNF_A_1256317_F0005_C){#F0005}

![H & E stained kidney histopathology micrographs of STZ group of rats before and after treatment with CSE, metformin and aspirin (×400). LT2D led to a widening of urinary space, overlaying cellular crescent fibrinohyalinosis, dilatation, vascularization, and necrosis and leukocyte infiltration. Treatment of STZ group with chicory may have improving effects. Aspirin apparently did not improve the structural situation; more dilatation and vascularization was observed, urinary space was still large and hyalinization was present.](IRNF_A_1256317_F0006_C){#F0006}

### Western blot analysis {#s0022}

The expression levels of SGLT1 and SGLT2 proteins increased significantly in the kidney tissue after diabetes induction (*p* \< .01). Treatment with CSE increased SGLT1 (*p* \< .01), but did not change the SGLT2 levels ([Figure 7](#F0007){ref-type="fig"}).

![Western blotting for SGLT1 and SGLT2 proteins in ET2D and LT2D before and after treatment with CSE. ♦*p* \< .01 versus Control; \**p* \< .01. Data are expressed as mean ± SD of two experiments.](IRNF_A_1256317_F0007_C){#F0007}

Discussion {#s0023}
==========

In diabetes, flesh and limbs flow into urine to produce alterations in urine and blood variables.[@CIT0022] To evaluate some of these variables, we created sets of diabetic animals with ET2D and LT2D (LT2D may be taken as equivalent to uncontrolled insulin-deficient diabetes). Increase in FBS and urine output, low insulin in ET2D and lack of insulin in LT2D rats, in addition to behavioral changes such as aggressiveness and fatigue, were a proof for diabetes induction. The significantly altered biochemical parameters are shown in bold and italic fonts in [Tables 1](#t0001){ref-type="table"} and [2](#t0002){ref-type="table"}.

In ET2D rats, CSE had ameliorating effects on FBS, urea, BUN, α-1-microglobulin, sodium, and potassium, in serum. In urine of ET2D rats, the most pronounced effect of CSE was on α-1-microglobulin levels. CSE and metformin were similar in causing a non-significant reduction in urine albumin levels, but only CSE was able to significantly lower urine α1-microglobulin. Although creatinine excretion increases in diabetes, the urinary protein levels are frequently normalized to urinary creatinine concentration.[@CIT0013] No significant change was observed in urinary albumin/creatinine or α1-microglobulin/creatinine ratios across the groups. It seemed that early engagement of the kidneys could be anticipated from abnormal absolute values of albumin, α1-microglobulin or total protein in urine rather than their creatinine ratios; only CSE seemed able to reverse the kidney problem and only α1-microglobulin was sensitive enough to successfully show improvements that followed treatment. α1-Microglobulin is a low molecular weight glycoprotein. The free form completely filters through the glomeruli and then is reabsorbed completely by normal proximal tubules. Its urine levels provide information about the renal filtration and reabsorption capacity of low molecular weight proteins.[@CIT0013]

Elevated uric acid in serum (\>8 mg/dl) and its low urinary excretion are associated with higher risk of T2D and increased chance of renal insufficiency by 3 fold in men and 10 fold in women.[@CIT0023] In the present study, uric acid levels in serum had a tendency to significantly decrease under CSE and metformin in LT2D. In diabetic animals, a better correlation coefficient between urine α~1~-microglobulin and serum uric acid (Pearson coefficient = .811) compared to that between urine albumin and serum uric acid (Pearson coefficient = .399) may support the concept that high serum uric acid can cause damage to the kidneys and lead to proteinuria; it may also suggest that α~1~-microglobulin was a better and a more sensitive candidate for the evaluation of kidney alleviation in the early stages of diabetes although the stability of α~1~-microglobulin in acidified urine may also be a factor.[@CIT0024]^,^[@CIT0027]

Without affecting blood and urine markers in ET2D, metformin was able to lower urinary glucose and urea, as well as serum urea and BUN levels, in LT2D. Aspirin significantly lowered urea and BUN in sera of LT2D rats but there was an unfavorable significant increase of creatinine in blood, indicating poor clearance of creatinine by the kidneys; there was a decrease in urine volume, glucose, uric acid, urea, and total protein levels of Asp-STZ group compared to the STZ group.

With regard to histology, renal tissues from ET2D and LT2D were different from normal and from each other. High intracellular glucose (glucotoxicity), deranged glucose metabolism, inflammation, oxidative stress, fibrosis and increased glomerular capillary pressure[@CIT0005]^,^[@CIT0028] can cause damage to renal structural components, the extent of which correlates with urinary albumin excretion.[@CIT0029] Some researchers have found the histological damages to kidneys to be unimpressive in STZ-induced diabetes attributing them to STZ toxicity, but Danda et al. found that low-dose STZ caused greater kidney lesions than high-dose STZ and concluded that the structural damage was not due to STZ nephrotoxicity.[@CIT0007]^,^[@CIT0030] Similarly, our results showed that urine albumin and total protein increased more significantly in ET2D than in LT2D. Among the common histological findings in diabetic kidney,[@CIT0005] we observed a widening of urinary space, overlaying cellular crescent fibrinohyalinosis, dilatation, vascularization, necrosis, and leukocyte infiltration. CSE seemed to alleviate the morphology in both types of T2D. This effect of CSE may originate from its anti-inflammatory effects [@CIT0016]^,^[@CIT0031] or its ability to reduce serum levels of uric acid or the size of glomerulus diameter that occurred in LT2D. Elevated uricemia has been linked to wall thickening, protein deposition, and smooth muscle cell proliferation in the kidney.[@CIT0007]

Despite the favorable effects on urine levels of glucose, uric acid, urea, and total proteins, aspirin seemed to increase the glomerular diameter. Glomerular enlargement is an important risk factor for various types of kidney diseases including chronic kidney disease (CKD).[@CIT0032] Metformin appeared to decrease the structural lesions as it has been reported to ameliorate pathological renal injury in T2D and prevent kidney cancer.[@CIT0033]

Increased glycosuria in diabetes can be associated with increased levels of sodium-dependent glucose transporters, including SGLT1 and SGLT2 proteins.[@CIT0036] Western blot analysis of these proteins suggested greater protein levels of both SGLT1 and SGLT2 in STZ- and NIA/STZ-induced diabetes in rats ([Figure 7](#F0007){ref-type="fig"}) in agreement with other studies.[@CIT0037] Despite the reported diuretic properties, chicory did not decrease the expression levels of SGLT1 nor SGLT2 proteins.[@CIT0038] As inhibition of both SGLT2 and SGLT1 inhibitors should lead to increased excretion of glucose in urine, the inability of CSE, metformin, and aspirin to inhibit SGLT2 and SGLT1protein expression could have been inferred from the observation that the amount of glucose in 24 h urine samples showed a continuous decrease (not an increase) during treatment.[@CIT0039] Instead, CSE tended to increase the expression of SGLT1. The effect of metformin and aspirin on SGLT1 or SGLT2 proteins were not evaluated, but metformin has been shown to increase the SGLT1 levels in duodenum and jejunum.[@CIT0040] Diuretic property of chicory may be related to its ability to slightly increase GRF (NIA/STZ vs. CSE-NIA/STZ, *p* = .057).

In summary, chicory benefited both types of diabetes with regard to histology, reduced serum uric acid and glomerular diameter in LT2D and lowered urinary α1-microglobulin in ET2D. The absolute values of albumin, α1-microglobulin or total protein in urine, not their creatinine ratios, were better markers for early renal damage. CSE was able to reverse kidney damage judging from its ability to significantly lower urine α1-microglobulin and improve histological appearance.
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